Peapod Lane Capital LLC Invests $577,000 in Whitehawk Therapeutics, Inc. $WHWK

Peapod Lane Capital LLC purchased a new stake in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 303,585 shares of the company’s stock, valued at approximately $577,000. Peapod Lane Capital LLC owned approximately 0.64% of Whitehawk Therapeutics at the end of the most recent quarter.

Separately, Vanguard Group Inc. acquired a new stake in Whitehawk Therapeutics during the 3rd quarter worth about $2,552,000. Institutional investors own 52.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on WHWK shares. JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Wall Street Zen lowered shares of Whitehawk Therapeutics to a “strong sell” rating in a research note on Saturday, November 1st. Oppenheimer began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Whitehawk Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.50.

Whitehawk Therapeutics Stock Performance

NASDAQ:WHWK opened at $3.05 on Monday. The company has a market capitalization of $143.75 million, a P/E ratio of 21.79 and a beta of 0.59. The stock’s 50 day moving average price is $2.71 and its 200 day moving average price is $2.29. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $3.77.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.